

Psychiatric morbidity and quality of life in children and adolescents with cystic fibrosis

Gülser Şenses-Dinç¹, Uğur Özçelik², Tuna Çak³, Deniz Doğru-Ersöz², Esra Çöp¹, Ebru Yalçın², Ebru Çengel-Kültür³, Sevgi Pekcan⁴, Nural Kiper², Fatih Ünal³

¹Clinics of Child and Adolescent Psychiatry, Ministry of Health Ankara Children's Health and Pediatric Hematology-Oncology Training and Research Hospital, Departments of ²Pulmonology and ³Child and Adolescent Psychiatry, Hacettepe University Faculty of Medicine, Ankara, and ⁴Pediatric Pulmonology, Selcuk University Meram Faculty of Medicine, Konya, Turkey. E-mail: gulserdinc@yahoo.com

Received: 14th June 2017, Revised: 7th August 2017, Accepted: 30th August 2017

SUMMARY: Şenses-Dinç G, Özçelik U, Çak T, Doğru-Ersöz D, Çöp E, Yalçın E, Çengel-Kültür E, Pekcan S, Kiper N, Ünal F. Psychiatric morbidity and quality of life in children and adolescents with cystic fibrosis. Turk J Pediatr 2018; 60: 32-40.

The aim of this study was to investigate psychiatric disorders, depression and anxiety levels, and quality of life in children and adolescents with cystic fibrosis (CF), and to compare them with those of children with non-cystic fibrosis (non-CF) bronchiectasis and healthy controls. A total of 103 children and adolescents aged 7-16 years (35 CF, 28 non-CF bronchiectasis, 40 healthy) were evaluated using The Schedule for Affective Disorders and Schizophrenia for School Aged Children (K-SADS), The Child Depression Inventory (CDI), The State-Trait Anxiety Inventories for Children (STAI-C) and the Pediatric Quality of Life Inventory (PedsQL)-C. The three groups were not statistically different with respect to age, sex, and familial sociodemographic variables. 80% of the children and adolescents in the CF group were diagnosed with a psychiatric disorder, which was significantly more compared to those of the two other groups. The CF group had significantly greater rates of depressive and oppositional defiant disorder and the non-bronchiectasis group had a significantly greater rate of anxiety disorder than the control group. The depression and anxiety symptom levels were significantly greater and the quality of life levels significantly lower in both the CF and non-CF bronchiectasis groups than the healthy controls. In the CF group, the presence of any associated psychiatric disorder led to significantly lower total and psychosocial quality of life scores. In conclusion, CF is associated with poorer QOL in childhood. In order to improve quality of life in CF, the psychiatric conditions of children and adolescents should also be evaluated and their follow-up and treatment should involve a multidisciplinary team approach.

Key words: cystic fibrosis, children, psychopathology, quality of life.

Cystic fibrosis (CF) is a genetic disorder with autosomal recessive transmission. Mutations in Cystic Fibrosis Transmembrane Regulator Gene result in diffuse dysfunction of exocrine glands, culminating in multi-organ involvement where the pulmonary involvement is the most common¹. As the main cause of morbidity and mortality in CF is respiratory involvement, the main goal of treatment is pulmonary protection.¹ In recent years, the advances in treatment approaches, and infection control have increased the average life expectancy of

CF patients. With increased life expectancy of children with CF, they and their families now face different difficulties. A substantially serious course of the disease, the time-consuming nature of its treatment, serious limitation of daily activities, and prognostic uncertainties create immense stress in patients and their families.^{1,2}

Although some studies have evaluated psychosocial adaptation and psychiatric morbidity in children and adolescents with CF, their results are rather inconsistent. Some

studies have reported adjustment problems, increased depression and anxiety levels, and a high rate of psychopathology in these children and adolescents³⁻⁵ whereas some others have indicated a comparable functionality with their healthy peers.^{2,6,7} Studies so far have reported anxiety disorders, depression, and oppositional defiant disorder as psychiatric disorders in children and adolescents with CF.^{3,8,9}

The concept of quality of life (QOL) is a multi-dimensional subjective assessment of one's own health and life. This concept encompasses various dimensions such as physical, psychological, and social wellness, and functionality.¹⁰ Modern interventions not only aim to provide a quantitative improvement, but also an improvement in quality of life. In CF, many factors affect quality of life. So far, studies of children and adolescents with CF have usually investigated the relationship between quality of life and sociodemographic features and physical health-related factors.¹¹⁻¹⁵ To date, many studies have examined the impact of a variety of clinical variables on QOL, which include pulmonary function tests (PFT), body mass index, infectious agents, hospitalization, malnutrition, and disease severity.¹²⁻¹⁵ Particularity, the forced expiratory volume 1 (FEV₁) value, which is used for determining the severity of the illness, has been widely expressed as a major factor affecting QOL.¹¹⁻¹³ In adults, on the other hand, psychosocial factors have also been studied. Although it has been mostly reported that psychological symptom level was high and it adversely affected QOL in adults with CF,^{4,16-18} there is a paucity of studies examining psychosocial factors with potential serious consequences on QOL in children and adolescents with CF. In children and adolescents with CF, hopelessness about future, stigmatization perception, and school absenteeism have been related to an impaired quality of life.^{8,19,20}

In these CF patients whose life expectancy has been prolonged, determining psychosocial factors affecting quality of life may bring about psychosocial interventions. As to the best of our knowledge, this study is the first to examine the relationship between psychiatric disorders diagnosed by a structured psychiatric interview and QOL in children and adolescents with

CF. This study aimed to evaluate psychiatric morbidity, the depression and anxiety levels, and QOL in children and adolescents with CF, and to compare them with those of non-cystic fibrosis (non-CF) bronchiectasis and healthy control groups. Additionally, we aimed to determine the relationship between psychosocial factors and QOL.

Material and Methods

Participants

This study included a total of 35 volunteers aged 7-16 years who were at follow-up for CF at Hacettepe University Faculty of Medicine, Pediatric Pulmonology outpatient clinic for a period of 1 year. The control groups included 28 patients with non-CF bronchiectasis matched for age and sex, and followed in the same clinic, as well as 40 healthy subjects matched for age and sex, who presented to the outpatient clinics of Hacettepe University for any acute physical health problems.

Measures

The Socio-demographic and Clinical Information Questionnaire (SCIQ): This is a form developed by the researchers to be used for each participant in the study. The PFT [forced expiratory volume 1 (FEV₁), forced vital capacity (FVC), forced expiratory flow 25–75% (FEF₂₅₋₇₅)] of the patients in the CF and non CF-bronchiectasis groups were accessed via medical records.

Hollingshead-Redlich Scale (HRS): Translated into Turkish by Kültür, the scale aims to determine a family's socioeconomic status (SES).²¹ The scale determines SES by taking into account the occupational and educational levels of both of the parents.

The Child Depression Inventory (CDI): This is a 27-item self-reported scale that can be applied to children aged 6-17 years.^{22,23} It rates depressive symptoms in the last 2 weeks, with higher scores indicating more depressive symptoms.

The State-Trait Anxiety Inventories for Children (STAI-C): This is a self-reported scale composed of two subscales each with 20 items, and it rates state and trait anxiety levels of children.^{24,25} State anxiety refers to anxiety symptoms under certain circumstances and trait anxiety to permanent individual features creating a tendency for anxiety perception. Higher scores

indicate a high anxiety level.

Schedule for Affective Disorders and Schizophrenia for School Aged Children-Present and Lifetime Version (K-SADS-PL): This is a semi-structured psychiatric interview applied by a clinician, which is developed to screen psychiatric disorders on the basis of DSM-III and DSM-IV diagnostic criteria in children and adolescents aged 6-18 years.²⁶ The validity and reliability of the Turkish version was tested by Gökler et al.²⁷ K-SADS-PL questions psychiatric disorders in accordance with the information obtained from the parents and the child, and the psychiatric diagnosis is made by incorporating the psychiatrist's observations.

The Pediatric Quality of Life Inventory Parent Version (PedsQL-P) and the Pediatric Quality of

Life Inventory Child Version (PedsQL-C): These were developed to rate health-related quality of lives of children and adolescents aged 2-18 years.¹⁰ It questions about the domains of physical health, emotional functionality, and social functionality, which are the properties of the state of healthiness as defined by the World Health Organization. This scale is being used in children with a variety of chronic medical conditions. It contains two subscales scores, namely psychosocial (PSH) and physical health (PH), and a total health (TH) score. The scale contains both parent and child versions for physical and psychosocial functioning, and a higher PedsQL total score indicates a better QOL. In this study, the PedsQL-P scale was administered to the caregiver. Memik et al.^{28,29}

Table I. Sociodemographic Properties and Pulmonary Function Tests.

	CF (n=35)	Non-CF bronchiectasis (n=28)	Control (n=40)	
Gender, n (%)				
Female	15 (42.9)	13 (46.4)	19 (47.5)	$\chi^2=0.172$
Male	20 (57.1)	15 (53.6)	21 (52.5)	$p=0.918$
Socioeconomic status, n (%)		2 (7.1)	10 (25.0)	
High	9 (25.7)	18 (64.3)	21 (52.5)	$\chi^2=6.343$
Medium	14 (40)	8 (28.6)	9 (22.5)	$p=0.197$
Low	12 (34.3)			
Age (months)*	156 (90-204)	165 (96-192)	149 (87-192)	$\chi^2=1.496$ $p=0.474$
Maternal age (years)*	37 (30-48)	41 (28-49)	40 (33-49)	$\chi^2=3.343$ $p=0.190$
Paternal age (years)*	41 (31-53)	44 (29-53)	42 (35-54)	$\chi^2=2.001$ $p=0.386$
Maternal education (years)*	5 (5-15)	5 (5-15)	5 (5-15)	$\chi^2=1.905$ $p=0.386$
Paternal education (years)*	8 (5-15)	9.5 (5-15)	11 (5-15)	$\chi^2=1.630$ $p=0.443$
Hospitalization rate, n (%)	32 (91.4)	22 (78.6)	-	$\chi^2=2.100$ $p=0.170$
Hospitalization number (frequency)*	6 (1-30)	2.5 (1-15)	-	$Z=-1.488$ $p=0.137$
Hospitalization duration (days)*	22 (3-300)	20 (1-180)	-	$Z=-1.036$ $p=0.300$
FEV ₁ *	93 (31-113)	77.5 (31-122)	-	$Z=-2.941$ $p=0.003$
FVC*	95 (48-125)	84.5 (36-136)	-	$Z=-2.532$ $p=0.011$
FEF ₂₅₋₇₅ *	71 (17-120)	55.5 (15-136)	-	$Z=-1.883$ $p=0.060$

FEV₁: forced expiratory volume 1, FVC: forced vital capacity, FEF₂₅₋₇₅: forced expiratory flow 25–75%, CF: cystic fibrosis

*Data is presented as median (min-max)

Table II. Depression and Anxiety Symptom Levels.

	CF (n=35)	Non-CF bronchiectasis (n=28)	Control (n=40)	
CDI	9 (0-26)	8 (2-28)	5 (0-15)	$\chi^2=11.324$ $p=0.003$
STAI-C (SA)	34 (21-48)	34 (24-48)	30 (21-47)	$\chi^2=9.041$, $p=0.011$
STAI-C (TA)	29 (20-39)	29 (23-55)	26 (20-37)	$\chi^2=7.304$, $p=0.026$

CDI: Child Depression Inventory, STAI-C/SA: State-Trait Anxiety Inventories for Children/ State Anxiety, STAI-C/TA: State-Trait Anxiety Inventories for Children/ Trait Anxiety
Data is presented as median (min-max).

performed the validity and reliability study in Turkish.

Procedure

The study was carried out in the Child and Adolescent Psychiatry Department of Hacettepe University İhsan Doğramacı Children's Hospital. It was approved by the Local Ethics Committee (FON 07/32). All subjects gave written assent and their parents' written informed consent for participating in the study. The SCIQ, HRS and the K-SADS-PL was carried out by a child and adolescent psychiatrist. Participating children and adolescents completed the CDI, STAI-C and the PedsQL-C and their mothers filled out the PedsQL-P.

Statistical analysis

The Statistical Package for the Social Sciences 17.0 was used for all statistic analyses. The Shapiro-Wilk test was used to determine the normality of the data. The three groups were compared with the Kruskal Wallis test. The categorical variables were compared with the Chi-square test and the Fisher's exact test. Spearman's correlation analysis was used for correlation analysis. A p value of less than 0.05 was considered statistically significant for paired comparisons and less than 0.017 for triple comparisons.

Results

This study included a total of 103 children and adolescents, 35 with CF, 28 with non-CF bronchiectasis, and 40 healthy controls. Of all participants, 45.6% were female and 54.4% were male, and their median age was 13 years (156 months). No significant differences were found between the three groups with regard to age, sex, SES, parental age and education level (Table I). Disease severity was described

using FEV₁ (>80 normal; 60-80 mild; 40-60 moderate; <40 severe). Accordingly, 74% of the CF group had normal FEV₁ values, 20% mild, 6% severe. In the Non-CF bronchiectasis group FEV₁ values were normal in 43%, mild in 46%, moderate in 7% and severe in 4%. A comparison of the CF and non-CF bronchiectasis groups with respect to PFT revealed that the FEV₁ and FVC values were significantly lower in patients with non-CF bronchiectasis (Table I).

All patients in the CF group had lung and pancreas involvement. In most patients (94.3%) with CF, the onset of symptoms was before the age of 1 year while the corresponding figure for non-CF bronchiectasis group was 50%. Chest physiotherapy was applied to all patients in the CF and non-CF bronchiectasis groups; and there was no significant difference between the CF and non-CF groups with respect to hospitalization rate, and the number and durations of hospitalizations (Table I).

Psychiatric morbidity

Eighty percent of children in the CF group were diagnosed to have at least one psychiatric disorder using the semi-structured clinical interview. These include, in the order of cumulative rates, anxiety disorders (54.3%), depressive disorders (20%), attention deficit hyperactivity disorder (17.1%), enuresis nocturna (11.4%), oppositional defiant disorder (8.5%), adjustment disorder (5.7%), obsessive compulsive disorder (5.7%) and tic disorders (2.8%). On the other hand, 50% of children in the non-CF bronchiectasis group diagnosed to have at least one psychiatric disorder, namely anxiety disorders (31.2%), obsessive compulsive disorder (10.7%), social phobia (10.7%), enuresis nocturna (10.7%), depressive

Table III. Quality of Life Levels.

	CF (n=35)	Non-CF bronchiectasis (n=28)	Control (n=40)	
PedsQL-P				
TH	72.8 (29.3-95.6)	66.3 (31.5-86.9)	94.5 (86-100)	$\chi^2=65.193$ p<0.001
PH	71.8 (28.1-100)	59.3 (31.2-84.3)	96.8 (87.5-100)	$\chi^2=63.087$ p<0.001
PSH	75 (28.3-96.6)	69.1 (31.6-93.3)	95 (80-100)	$\chi^2=53.985$ p<0.001
PedsQL-C				
TH	79.3 (52.1-98.9)	71.1 (30.4-96.7)	94.5 (86.6-100)	$\chi^2=54.752$ p<0.001
PH	78.1 (42.8-100)	65.5 (28.1-93.7)	93.7 (87.5-100)	$\chi^2=56.891$ p<0.001
PSH	81.6 (45-98.3)	75.8 (31.6-100)	93.3 (83.3-100)	$\chi^2=46.461$ p<0.001

PedsQL-P: Pediatric Quality of Life Inventory Parent Version, PedsQL-C: the Pediatric Quality of Life Inventory Child Version, PSH: psychosocial scores, PH: physical health scores; TH: total health scores
Data is presented as median (min-max).

disorders (3.6%), simple phobia (3.6%), adaptation disorder (3.6%) and tic disorders (3.6%). In the healthy control group the rate of a psychiatric disorder was 20%. The rates of psychiatric diagnosis were significantly different between the three groups ($\chi^2=26.936$ p<0.001); the CF group had a significantly higher rate of psychiatric disorders than the two other groups ($\chi^2=6.300$ p=0.012; $\chi^2=26.923$ p<0.001); the rate of psychiatric disorders was also higher in the non-CF bronchiectasis group than the control group ($\chi^2=6.773$ p=0.009). The CF group had significantly higher rates of depressive disorders and oppositional defiant disorder; the non-CF bronchiectasis group had a significantly higher rate of anxiety disorders than the control group ($\chi^2=11.368$ p=0.003; $\chi^2=8.085$ p=0.018; $\chi^2=6.071$ p=0.014; $\chi^2=9.937$, p=0.002). The rates of psychiatric diagnosis did not differ in terms of sex and SES ($\chi^2=0.104$ p=0.747; $\chi^2=2.452$ p=0.293).

There was a significant difference between the three groups with respect to depression and state anxiety symptoms determined with CDI and STAI-C (Table II). Paired comparisons between the groups revealed that the difference originated from the healthy control group, and there were no significant differences between the CF and non-CF groups (p=0.073; p=0.004; p=0.004; p=0.07; p=0.016; p=0.008). The anxiety and depression symptoms in both groups were not related to patient's age, parental age or education level, or number and duration of hospitalizations. Depressive symptoms were positively correlated with the

increasing number of medications used in both CF and non-CF bronchiectasis groups (r=0.349, p=0.040; r=0.423, p=0.025). In the CF group, the depression symptoms were negatively correlated with FEV₁ (r=-0.354, p=0.037), FVC (r=-0.462, p=0.005), and FEF₂₅₋₇₅ (r=-0.382, p=0.024) and again the trait anxiety symptoms showed a moderate negative correlation with FEV₁ (r=-0.455, p=0.006), FVC (r=-0.554, p=0.001) and FEF₂₅₋₇₅ (r=-0.349, p=0.040).

Quality of life

The quality of life scores determined by both PedsQL-P and PedsQL-C were significantly different between the three groups (Table III). Paired comparisons between the groups revealed that the statistical significance was derived from the healthy control group (p<0.001), with the CF and non-CF bronchiectasis groups being similar with respect to total score, physical health score, and psychosocial health score of QOL reported by both children and mothers. (p=0.215; p=0.566; p=0.489).

In CF and non-CF bronchiectasis groups there were no significant correlations between sex, SES, hospitalization and quality of life levels reported by children or mothers. In the CF group, children with a psychiatric diagnosis had significantly lower child-rated QOL scores (PedsQL-CTH Z=-2.043 p=0.039; PedsQL-CPH Z=-2.065 p=0.039; PedsQL-CPSH Z=-1.882 p=0.052). Separate analyses for depressive disorders and anxiety disorders revealed that in the CF group children diagnosed with

Table IV. Factors Related to Quality of Life Levels in Cystic Fibrosis and Non-CF Bronchiectasis Groups.

	Age	CDI	STAI-C TA	STAI-C SA	FEV ₁	FVC	FEF ₂₅₋₇₅
CF							
PedsQL-P/TH	0.002	-0.314	-0.283	-0.050	0.212	-0.023	0.378*
PedsQL-P/PH	0.039	-0.208	-0.264	-0.077	0.183	-0.071	0.211
PedsQL-P /PSH	0.047	-0.352*	-0.284	-0.040	0.210	-0.031	0.436**
PedsQL-C/TH	0.051	-0.608**	-0.702**	-0.181	0.334*	0.266	0.479**
PedsQL-C/PH	0.141	-0.427*	-0.540*	-0.150	0.171	0.117	0.179
PedsQL-C/PSH	0.070	-0.659**	-0.707**	-0.227	0.330	0.273	0.528**
Non-CF Bronchiectasis							
PedsQL-P/TH	0.107	0.212	0.281	-0.537**	0.241	0.194	0.114
PedsQL-P/PH	-0.069	0.058	0.055	-0.311	0.117	0.169	0.163
PedsQL-P/PSH	0.148	-0.478*	-0.656**	-0.480**	0.272	0.128	0.176
PedsQL-C/TH	0.113	-0.608**	-0.702**	-0.181	0.064	0.093	0.145
PedsQL-C/PH	0.046	-0.265	-0.651**	-0.503**	0.268	0.314	0.032
PedsQL-C/PSH	0.128	-0.582**	-0.577**	-0.334	0.044	0.017	0.251

PedsQL-P: Pediatric Quality of Life Inventory Parent Version, PedsQL-C: the Pediatric Quality of Life Inventory Child Version, PSH: psychosocial scores, PH: physical health scores, TH: total health scores, CDI: Child Depression Inventory, STAI-C/SA: State-Trait Anxiety Inventories for Children/ State Anxiety, STAI-C/TA: State-Trait Anxiety Inventories for Children/ Trait Anxiety, FEV₁: forced expiratory volume 1, FVC: forced vital capacity, FEF₂₅₋₇₅: forced expiratory flow 25-75%, *:*p*<0.05; **:*p*<0.01

depressive disorders had significantly lower TH scores and PSH scores reported by both mothers and children (*Z* = -2.826 *p* = 0.003; *Z* = -2.888 *p* = 0.003; *Z* = -2.455 *p* = 0.012; *Z* = -2.933 *p* = 0.092).

The correlation of QOL with anxiety and depression symptoms and PFT were also studied (Table IV). In the CF group, the PSH level reported by mothers and all QOL levels reported by children showed a significant inverse correlation with depressive symptoms. A significant inverse correlation was found between QOL levels and trait anxiety symptoms in both the CF and the non-CF bronchiectasis groups. There was a significant positive correlation between TH scores reported by children and FEV₁, and the TH and PSH scores reported by children and mothers and FEF₂₅₋₇₅ (Table IV).

Discussion

This cross-sectional study compared QOL and related factors (psychiatric disorders, sociodemographic variables, disease severity) between children and adolescents with CF, and non-CF bronchiectasis, i.e. a separate, non-

fatal chronic respiratory disorder, and healthy age-matched peers. A review of the literature did not identify any other study comprising these three groups in a similar study design.

Our study revealed that the psychopathology rates were higher in children with CF. Whereas previous studies have reported lower rates of psychiatric disorders in CF groups, the most commonly encountered disorders have been anxiety disorder and depression, as noted in our study.^{2,8,9,30,31} Those studies have usually used either self-reported scales, parent reports or unstructured interviews. We believe that a greater rate of psychiatric diagnoses likely resulted from the structured interview technique used in our study and also the lack of adequate psychosocial support for these children in our country.

Depression and state anxiety symptoms were higher in both the CF and non-CF bronchiectasis groups. Studies employing self-reported scales in children and adolescents with CF have produced inconsistent results related to depression and anxiety levels or symptoms.^{2-4,32} In the only study where children

and adolescents with non-CF bronchiectasis were studied, depression and state anxiety levels of these groups were comparable to those of the healthy group, although trait anxiety level was higher.³³ Our findings are supportive of literature studies reporting higher depression and anxiety symptoms. Furthermore, higher depression and anxiety symptoms are consistent with the finding of high psychiatric comorbidity rate in both chronic disorders.

The main finding of our study is that the pediatric quality of life TH scores, PH scores, and PSH scores reported by both mothers and children were lower in children in the CF and non-CF bronchiectasis groups than those in the control group. So far, only two studies separately compared children with CF and non-CF bronchiectasis with their healthy peers.^{33,34} Similar to our results, those studies reported worse perception of quality of life among children with both CF and non-CF bronchiectasis.

Few studies have compared CF and other chronic disorders in terms of quality of life. One study used population sample as a healthy control group.³⁵ In the study conducted by Sawyer et al.³⁵ it was shown that CF and other chronic disease groups perceived health-related quality of life worse than the population sample in many domains. Previous comparisons of children with CF with other chronic disease groups have produced conflicting results. While it has been reported that children with CF had a better overall health perception and had a lower rate of emotional problems compared with children with chronic physical disorders,^{35,36} one study has reported worse psychosocial health and emotional functionality.¹³ Only one study found comparable results between CF and other chronic groups.³⁶ Our findings indicate comparable QOL levels between CF and non-CF bronchiectasis groups. Considering that CF is a fatal disease with multiorgan involvement, it may be expected to have a deeper adverse impact on patients' QOL. However, lower FEV₁ and FVC values in the non-bronchiectasis group but similar clinical characteristics such as number and duration of hospitalizations, and chest physiotherapy may have had unfavourably impact on quality of life scores in this group.

Among factors potentially affecting QOL, age

and sex were not found to be correlated with QOL as reported by children and mothers. Although inconsistent results have been reported about these demographic variables in the literature, girls have been shown to have a worse QOL, and QOL was better at the prepubertal period.^{7,18,37-39} Our findings suggest that clinical characteristics and psychosocial variables may be more important for QOL rather than age and sex.

Although the negative effect of growth retardation and hospitalization on quality of life has been previously shown, this study failed to demonstrate their correlation with QOL. On the other hand, it indicated a positive correlation between quality of life and FEV₁, FEF₂₅₋₇₅ in the CF group. This finding supports the studies that have indicated the effect of respiratory function on QOL. Having said that, positive correlations between FEV₁, FVC, and FEF₂₅₋₇₅ values and depression and anxiety symptoms are noteworthy for showing a possible relationship between pulmonary function and psychological status.

Our study demonstrated an association between a lower QOL and depression and trait anxiety symptoms in children with CF. Despite the lack of pediatric studies exploring the relationship between depression and anxiety symptoms and QOL in CF, adult studies have indicated a negative effect of anxiety and depression on various domains of QOL.¹⁶⁻¹⁸ Similar to adult studies, our study supported the hypothesis that depression and anxiety impact QOL. In parallel with these findings, psychiatric disorders also adversely affect children reported QOL. In CF, accompanying depression is closely related to overall and psychosocial quality of life. Importantly, the present study showed a relationship between a clinician-made diagnosis of depression with quality of life in CF. Most researchers have indicated that children with chronic disorders are at risk emotionally, socially, cognitively, and behaviorally.⁴⁰ In particular, psychiatric comorbidities, particularly depression may unfavorably influence the life and disease management of patients with CF. Both anxiety and depression have been described as risk factors for a poor treatment compliance, increased mortality, and a lower chance of getting proper healthcare in chronic conditions.^{5,16} Therefore, screening for

psychiatric symptoms and disorders may aid in prevention of risk factors and development of treatment programs in CF.

The main limitation of the present study is the small sample size. Additionally, sampling from a single center limits the generalizability of its principal findings. Finally, owing to its cross-sectional nature, it falls short in evaluating temporary changes in quality of life between groups and establishing causal relationships. Its strengths include the use of a semi-structured interview, the use of evaluation tools with proven validity and reliability, and the inclusion of two separate control groups (a chronic disease group and healthy control group).

In conclusion, quality of life is poor in childhood in CF. This study is scientifically important for revealing that psychiatric symptoms/diagnoses are prevalent, adversely affecting quality of life of children and adolescents with CF. In these patients, an assessment of quality of life should be a part of the treatment, aiming at its improvement. In order to achieve this goal, psychiatric states of children and their parents should be evaluated and necessary interventions be applied. These patients should be treated by a multidisciplinary team. Psychosocial risk factors affecting quality of life in this disorder should be further studied in longitudinal studies involving larger populations.

REFERENCES

- Castellani C, Assael BM. Cystic fibrosis: a clinical view. *Cell Mol Life Sci* 2017; 74: 129-140.
- Bregnballe V, Thastum M, Schiøtz PO. Psychosocial problems in children with cystic fibrosis. *Acta Paediatr* 2007; 96: 58-61.
- Thompson RJ, Gustafson KE, Gil KM, Godfrey J, Murphy LM. Illness specific patterns of psychological adjustment and cognitive adaptational processes in children with cystic fibrosis and sickle cell disease. *J Clin Psychol* 1998; 54: 121-128.
- Modi AC, Driscoll KA, Montag-Leifling K, Acton JD. Screening for symptoms of depression and anxiety in adolescents and young adults with cystic fibrosis. *Pediatr Pulmonol* 2011; 46: 153-159.
- Quittner AL, Goldbeck L, Abbott J, et al. Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of The International Depression Epidemiological Study across nine countries. *Thorax* 2014; 69: 1090-1097.
- Thompson RJ, Hodges K, Hamlett KW. A matched comparison of adjustment in children with cystic fibrosis and psychiatrically referred and nonreferred children. *J Pediatr Psychol* 1990; 15: 745-759.
- Szyndler JE, Towns SJ, van Asperen PP, McKay KO. Psychological and family functioning and quality of life in adolescents with cystic fibrosis. *J Cyst Fibros* 2005; 4: 135-144.
- Smith BA, Wood BL. Psychological factors affecting disease activity in children and adolescents with cystic fibrosis: medical adherence as a mediator. *Curr Opin Pediatr* 2007; 19: 553-558.
- White T, Miller J, Smith GL, McMahon WM. Adherence and psychopathology in children and adolescents with cystic fibrosis. *Eur Child Adolesc Psychiatry* 2009; 18: 96-104.
- Varni JW, Seid M, Rode CA. The PedsQL: measurement model for the Pediatric Quality of Life Inventory. *Med Care* 1999; 37: 126-139.
- Habib AR, Manji J, Wilcox PG, Javer AR, Buxton JA, Quon BS. A systematic review of factors associated with health-related quality of life in adolescents and adults with cystic fibrosis. *Ann Am Thorac Soc* 2015; 12: 420-428.
- Bodnar R, Kadar L, Holics K, et al. Factors influencing quality of life and disease severity in Hungarian children and young adults with cystic fibrosis. *Ital J Pediatr* 2014; 40: 50.
- BodnárR, Kádár L, Szabó L, Hernádi M, Mikóczi M, Mészáros Á. Health related quality of life of children with chronic respiratory conditions. *Adv Clin Exp Med* 2015; 24: 487-495.
- Gee L, Abbott J, Conway SP, Etherington C, Webb AK. Quality of life in cystic fibrosis: the impact of gender, general health perceptions and disease severity. *J Cyst Fibros* 2003; 2: 206-213.
- Abbott J, Morton AM, Hurley MA, Conway SP. Longitudinal impact of demographic and clinical variables on health-related quality of life in cystic fibrosis. *BMJ Open* 2015; 19: 5:e007418
- Havermans T, Colpaert K, Dupont LJ. Quality of life in patients with Cystic Fibrosis: association with anxiety and depression. *J Cyst Fibros* 2008; 7: 581-584.
- Yohannes AM, Willgoss TG, Fatoye FA, Dip MD, Webb K. Relationship between anxiety, depression, and quality of life in adult patients with cystic fibrosis. *Respir Care* 2012; 57: 550-556.
- Riekert KA, Bartlett SJ, Boyle MP, Krishnan JA, Rand CS. The association between depression, lung function, and health-related quality of life among adults with cystic fibrosis. *Chest* 2007; 132: 231-237.
- Borawska-Kowalczyk U, Bodnar R, Meszaros A, Sands D. Comparison of health-related quality of life among children with cystic fibrosis and their parents in two Eastern European countries. *J Cyst Fibros* 2015; 14: 798-804.
- Oliver NK, Free LM, Bok C, McCoy SK, Lemanek LK, Emery FC. Stigma and optimism in adolescents and young adults with cystic fibrosis. *J Cyst Fibros* 2014; 13: 737-744.
- Çengel Kültür SE, Ünal MF, Özusta Ş. Alkol bağımlılığı olan babaların çocuklarında psikopatoloji. *Türk Psikiyatri Dergisi* 2006; 17: 3-11.
- Kovacs M. Rating scale to assess depression in school

- aged children. *Acta Paedopsychiatr* 1981; 46: 305-315.
23. Öy B. Çocuklar için depresyon ölçeği: Geçerlik ve güvenilirlik. *Türk Psikiyatri Dergisi* 1991; 2: 132-136.
 24. Spielberger CD. *Manual for the state-trait anxiety inventory for children*. Palo Alto: Consulting Psychologists Press, 1973.
 25. Özusta S. Turkish standardization, reliability and validity of State Trait Anxiety Inventory for children. *Turk J Psychol* 1995; 10: 32-44.
 26. Kaufman J, Birmaher B, Brent D, et al. Schedule for affective disorders and schizizophrenia for school-age children-present and lifetimeversion (K-SADS-PL): initial reliability and validity data. *J Am Acad Child Adolesc Psychiatry* 1997; 36: 980-988.
 27. Gökler B, Ünal F, Pehlivan Türk B, Çengel Kültür E, Akdemir D, Taner Y. Okul çağı çocukları için duygulanım bozuklukları ve şizofreni görüşme çizelgesi – şimdi ve yaşam boyu şekli-Türkç uyarlamasının geçerlik ve güvenilirliği. *Çocuk ve Gençlik Ruh Sağlığı Dergisi* 2004; 11: 109-116.
 28. Çakın Memik N, Ağaoglu B, Coskun A, Karakaya I. Çocuklar için yaşam kalitesi ölçeğinin 8-12 yaş çocuk formunun geçerlik ve güvenilirliği. *Çocuk ve Gençlik Ruh Sağlığı Dergisi* 2008; 15: 87-98.
 29. Çakın Memik N, Ağaoglu B, Coskun A, Üneri OŞ, Karakaya I. Çocuklar için yaşam kalitesi ölçeğinin 13-18 yaş ergen formunun geçerlik ve güvenilirliği. *Türk Psikiyatri Dergisi* 2007; 18: 353-363.
 30. Thompson RJ Jr, Hodges K, Hamlett KW. A matched comparison of adjustment in children with cystic fibrosis and psychiatrically referred and nonreferred children. *J Pediatr Psychol* 1990; 15: 745-759.
 31. Thompson RJ, Gustafson KE, Hamlett KW, Spock A. Psychological adjustment of children with cystic fibrosis: the role of child cognitive processes and maternal adjustment. *J Pediatr Psychol* 1992; 17:741-755.
 32. Pearson DA, Pumariega AJ, Seilheimer DK. The development of psychiatric symptomatology in patients with cystic fibrosis. *J Am Acad Child Adolesc Psychiatry* 1991; 30: 290-297.
 33. Bahali K, Gedik AH, Bilgic A, et al. The relationship between psychological symptoms, lung function and quality of life in children and adolescents with non-cystic fibrosis bronchiectasis. *Gen Hosp Psychiatry* 2014; 36: 528-532.
 34. Kianifar HR, Bakhshoodeh B, Hebrani P, Behdani F. Quality of life in cystic fibrosis children. *Iran J Pediatr* 2013; 23: 149-153.
 35. Sawyer MG, Reynolds KE, Couper JJ, et al. Health-related quality of life of children and adolescents with chronic illness-a two year prospective study. *Qual Life Res* 2004; 13: 1309-1319.
 36. Ingerski LM, Modi AC, Hood KK, et al. Health-related quality of life across pediatric chronic conditions. *J Pediatr* 2010; 156: 639-644.
 37. Groeneveld IF, Sosa ES, Pérez M, et al. Health-related quality of life of Spanish children with cystic fibrosis. *Qual Life Res* 2012; 21: 1837-1845.
 38. Cohen MA, Ribeiro MÂ, Ribeiro AF, Ribeiro JD, Morcillo AM. Quality of life assessment in patients with cystic fibrosis by means of the Cystic Fibrosis Questionnaire. *J Bras Pneumol* 2011; 37: 184-192.
 39. Hegarty M, Macdonald J, Watter P, Wilson C. Quality of life in young people with cystic fibrosis: effects of hospitalization, age and gender and differences in parent/child perceptions. *Child Care Health Dev* 2009; 35: 462-468.
 40. Barlow JH, Ellard DR. The psychosocial well-being of children with chronic disease, their parents and siblings: an overview of the research evidence base. *Child Care Health Dev* 2006; 32: 19-31.